Anifrolumab, a relatively emerging monoclonal antibody, is generating considerable excitement within the medical community as a potential solution for various immune-related conditions. This innovative agent targets https://bookmark-dofollow.com/story28388216/anifrolumab-a-promising-therapy-for-self-reactive-diseases